Superluminal Medicines, Inc. filed a Form D with the Securities and Exchange Commission on 2026-09-03.
Superluminal Medicines, Inc. filed a Form D notice of an exempt securities offering with the SEC on September 3, 2026. The filing reports $65.48M sold. Its industry group is Biotechnology. It names CONY D'CRUZ (Executive Officer, Director, Promoter), NANDITA SHANGARI (Director), DYLAN MORRIS (Director) (SEC Form D, September 3, 2026).
Sell to companies like Superluminal Medicines, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-09-03 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Superluminal Medicines, Inc.
Free to see. No signup.
More on the people and the money behind Superluminal Medicines, Inc., from the filings we hold.
Biotechnology raises by companies based in Massachusetts, filed in September 2026, largest first.
Get an email when Superluminal Medicines, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Superluminal Medicines, Inc. raises, hires or launches. No email unless you switch it on.
Watch Superluminal Medicines, Inc. →Get the full cited report on Superluminal Medicines, Inc.
What the filing shows about Superluminal Medicines, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Superluminal Medicines, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Superluminal Medicines, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Superluminal Medicines, Inc. See pricing
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $65.48M, on the same scale — one filing against the whole group's total, so it sits low by construction.
By form type: D ×4.
What the filing shows about Superluminal Medicines, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Superluminal Medicines, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Superluminal Medicines, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The 4 most recent of 4 filings on CIK 0001989478, filed as Superluminal Medicines, Inc.. Read from the SEC's own submissions feed for this issuer, not from a third party. Incorporated in DE. Full history on sec.gov.
Cony D'Cruz is named as Executive Officer and Director and Promoter on the Form D that Superluminal Medicines, Inc. filed with the SEC on 3 September 2026, one of 5 people that filing names.
Public records were searched under this name on 10 September 2026 — the federal exclusions list and SEC investment-adviser registration, including that register's own disclosure flag. Nothing came back. Names repeat and nothing here was matched on an identifier, so this is not a background check, and an absence from a register is not a clearance.
Nandita Shangari is named as Director on the Form D that Superluminal Medicines, Inc. filed with the SEC on 3 September 2026, one of 5 people that filing names.
Public records were searched under this name on 10 September 2026 — the federal exclusions list and SEC investment-adviser registration, including that register's own disclosure flag. Nothing came back. Names repeat and nothing here was matched on an identifier, so this is not a background check, and an absence from a register is not a clearance.
Dylan Morris is named as Director on the Form D that Superluminal Medicines, Inc. filed with the SEC on 3 September 2026, one of 5 people that filing names.
Diamantis Xylas is named as Director on the Form D that Superluminal Medicines, Inc. filed with the SEC on 3 September 2026, one of 5 people that filing names.
Public records were searched under this name on 10 September 2026 — the federal exclusions list and SEC investment-adviser registration, including that register's own disclosure flag. Nothing came back. Names repeat and nothing here was matched on an identifier, so this is not a background check, and an absence from a register is not a clearance.
Harsha Paladugu is named as Director on the Form D that Superluminal Medicines, Inc. filed with the SEC on 3 September 2026, one of 5 people that filing names.
Public records were searched under this name on 10 September 2026 — the federal exclusions list and SEC investment-adviser registration, including that register's own disclosure flag. Nothing came back. Names repeat and nothing here was matched on an identifier, so this is not a background check, and an absence from a register is not a clearance.
5 people named on the filing — 1 holding an executive role and 4 as directors only.
Named as of the 2026-09-03 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Superluminal Medicines, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Superluminal Medicines, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Superluminal Medicines, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises, week of 2026-08-31 · Biotech raises in Boston
https://mentionfox.com/funding/superluminal-medicines-inc-form-d-000001